76.43

6.95% 4.97

10 X Genomics Inc (TXG)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$71.46

Aprire:

$70.92

Volume 24 ore:

1.75M

Relative Volume:

0.40

Capitalizzazione di mercato:

$9.96B

Reddito:

$638.78M

Utile/perdita netta:

$-22.66M

Rapporto P/E:

-438.25

EPS:

-0.1744

Flusso di cassa netto:

$122.18M

1 W Prestazione:

+4.56%

1M Prestazione:

-3.38%

6M Prestazione:

+232.74%

1 anno Prestazione:

+486.57%

Intervallo 1D:

$70.10

$77.55

Intervallo di 1 settimana:

$67.52

$73.99

Portata 52W:

$11.87

$102.81

10 X Genomics Inc Stock (TXG) Company Profile

Nome

10 X Genomics Inc

Settore

Healthcare (1052)

Industria

Medical Devices (142)

Telefono

(925) 401-7300

Indirizzo

6230 STONERIDGE MALL ROAD, PLEASANTON, CA

Dipendente

1,178

Cinguettio

@10xgenomics

Prossima data di guadagno

2026-11-05

Ultimi documenti SEC

TXG's Discussions on Twitter

Compare TXG vs ABT, MDT, SYK, BSX, EW

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
TXG 10 X Genomics Inc	76.43	9.96B	638.78M	-22.66M	122.18M	-0.1744
ABT Abbott Laboratories	98.22	169.95B	46.59B	5.41B	7.38B	3.0938
MDT Medtronic Plc	93.39	119.46B	36.36B	4.84B	5.43B	3.7261
SYK Stryker Corp	296.91	113.89B	25.27B	3.34B	4.57B	8.6334
BSX Boston Scientific Corp	44.50	64.49B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	87.96	50.70B	6.30B	1.07B	1.09B	1.8406

10 X Genomics Inc Stock (TXG) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-09-28	Iniziato	Argus	Buy
2026-09-09	Ripresa	UBS	Neutral
2026-09-01	Iniziato	RBC Capital Mkts	Sector Perform
2026-03-31	Aggiornamento	William Blair	Mkt Perform → Outperform
2025-12-11	Downgrade	Citigroup	Buy → Neutral
2025-12-02	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2025-09-11	Iniziato	Piper Sandler	Neutral
2025-02-13	Downgrade	Leerink Partners	Outperform → Market Perform
2024-09-03	Iniziato	Leerink Partners	Outperform
2024-07-22	Aggiornamento	Jefferies	Hold → Buy
2024-07-18	Downgrade	JP Morgan	Overweight → Neutral
2024-07-10	Downgrade	Deutsche Bank	Buy → Hold
2024-06-27	Downgrade	Wolfe Research	Outperform → Peer Perform
2024-06-25	Downgrade	Guggenheim	Buy → Neutral
2024-06-03	Ripresa	Jefferies	Hold
2024-05-01	Downgrade	TD Cowen	Buy → Hold
2023-12-14	Iniziato	Guggenheim	Buy
2023-12-13	Iniziato	Wolfe Research	Outperform
2023-12-12	Aggiornamento	BofA Securities	Underperform → Neutral
2023-07-05	Ripresa	JP Morgan	Overweight
2023-05-10	Iniziato	Barclays	Overweight
2023-03-31	Iniziato	Stephens	Overweight
2023-02-02	Iniziato	UBS	Neutral
2022-12-14	Iniziato	Deutsche Bank	Buy
2022-08-18	Downgrade	Goldman	Neutral → Sell
2022-07-25	Iniziato	Canaccord Genuity	Buy
2022-07-15	Downgrade	BofA Securities	Neutral → Underperform
2022-07-15	Downgrade	William Blair	Outperform → Mkt Perform
2021-10-15	Ripresa	Cowen	Outperform
2021-09-14	Downgrade	BofA Securities	Buy → Neutral
2021-03-15	Iniziato	William Blair	Outperform
2020-12-02	Iniziato	Goldman	Neutral
2020-09-09	Iniziato	Morgan Stanley	Overweight
2020-07-10	Iniziato	Stifel	Buy
2020-03-05	Iniziato	Guggenheim	Buy
2020-01-07	Iniziato	Citigroup	Buy
2019-10-07	Iniziato	BofA/Merrill	Buy
2019-10-07	Iniziato	Cowen	Outperform
2019-10-07	Iniziato	JP Morgan	Overweight
2019-09-24	Iniziato	Evercore ISI	Outperform

Mostra tutto

10 X Genomics Inc Borsa (TXG) Ultime notizie

Oct 20, 2026

Single Cell Sequencing Market Forecast to 2035: Services, Technologies, End-users, Applications, and Regions | 15% CAGR Drives Drug Discovery and Precision Medicine Growth - GlobeNewswire Inc.

Oct 20, 2026

Oct 15, 2026

TXG 10-Q & SEC FilingsYahoo Finance - Yahoo! Finance Canada

Oct 15, 2026

Oct 08, 2026

10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research - Zacks Investment Research

Oct 08, 2026

Oct 07, 2026

ARK and Catherine D. Wood report ownership above 5% in 10x Genomics (TXG). - Stock Titan

Oct 07, 2026

Oct 06, 2026

Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and Automation - GlobeNewswire Inc.

Oct 06, 2026

Sep 30, 2026

10x Genomics Begins Atera Shipments as Spatial Biology Demand Rises - Zacks Investment Research

Sep 30, 2026

Sep 24, 2026

10x genomics director Shehnaaz Suliman sells $464,667 in stock - Investing.com

Sep 24, 2026

Form 4 10X Genomics Inc For: 24 September By Investing.com - Investing.com India

Sep 24, 2026

10x genomics director Shehnaaz Suliman sells $464,667 in stock By Investing.com - Investing.com Canada

Sep 24, 2026

Form 4 10X Genomics Inc For: 24 September By Investing.com - Investing.com UK

Sep 24, 2026

10x genomics director Shehnaaz Suliman sells $464,667 in stock By Investing.com - Investing.com UK

Sep 24, 2026

Under a trading plan, a 10x Genomics (TXG) director sells 5,723 shares in five transactions. - Stock Titan

Sep 24, 2026

At $77.75 to $82.53 a share, 10x Genomics (TXG) CEO made five sales under a trading plan. - Stock Titan

Sep 24, 2026

10x Genomics Insider Sold Shares Worth $464,668, According to a Recent SEC Filing - Yahoo Finance

Sep 24, 2026

Sep 22, 2026

5,723 10x Genomics (NASDAQ: TXG) shares set for Rule 144 sale - Stock Titan

Sep 22, 2026

Sep 12, 2026

Korea's Lunit announces collaboration with 10x Genomics for AI-enabled pathology analysis of cancer - BioSpectrum Asia

Sep 12, 2026

Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know - Yahoo Finance

Sep 12, 2026

Sep 11, 2026

10x Genomics (TXG) CFO Adam Taich Sells 46,388 Shares - GuruFocus

Sep 11, 2026

10x genomics CFO Adam Taich disposes of $2.99 million in company stock - Investing.com Nigeria

Sep 11, 2026

10x genomics CFO Adam Taich disposes of $2.99 million in company stock - Investing.com

Sep 11, 2026